Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Curis has announced that its collaborator Genentech has achieved partial responses in advanced basal cell carcinoma tumors in the ongoing Phase I clinical trial of GDC-0449, which is being developed pursuant to the companies June 2003 collaboration agreement.
Subscribe to our email newsletter
Genentech has stated that it plans to initiate three Phase II clinical trials of GDC-0449 in 2008, which include a trial in metastatic colorectal cancer during the first quarter of 2008 and trials in advanced basal cell carcinoma and in an undisclosed advanced solid tumor of epithelial origin during the second half of 2008.
In connection with the treatment of the first patient in the Phase II colorectal cancer trial, Curis has the right to receive a $3 million cash milestone payment from Genentech. Curis also has the right to receive an additional $3 million cash payment upon initiation of the Phase II testing of the undisclosed advanced epithelial solid tumor.